ПРОБЛЕМА ОСТЕОПОРОЗА ПРИ АНКИЛОЗИРУЮЩЕМ СПОНДИЛИТЕ
Аннотация
Об авторах
Т. А. РаскинаРоссия
О. С. Малышенко
Россия
О. А. Пирогова
Россия
И. И. Григорьева
Россия
Список литературы
1. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике // Науч-нопрактическая ревматология. 2014. Т.52. № 4. С. 362-365
2. Van den Bussche H, Schön G, Kolonko T, Hansen H, Wegscheider K, Glaeske G, et al. Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity - results from a claims data based observational study in Germany. BMC Geriatr. 2011; 11: 54. doi: 10.1186/1471-2318-11-54
3. Ревматология. Российские клинические рекомендации / под ред. Е.Л. Насонова. Москва: ГЭОТАР-Медиа, 2017. 456 с
4. Годзенко А.А. Внескелетные проявления анкилозирующего спондилита: клиника, течение, прогноз: автореф. дис. … д-ра мед. наук. Москва, 2018. 38 с
5. Мясоутова Л.И., Лапшина С.А., Салихов И.Г., Васильева А.Г. Изменение минеральной плотности костной ткани у больных анкилозирующим спондилоартритом // Остеопороз и остеопатии. 2011. Т. 14. № 3. С.14-18
6. Губарь Е.Е., Эрдес Ш.Ф. Остеопороз у больных анкилозирующим спондилитом // Научно-практическая ревматология. 2013. Т. 51. № 5. С. 553-562
7. Deminger A, Klingberg E, Lorentzon M, Geijer M, Göthlin J, Hedberg M, et al. Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther. 2017; 19 (1): 273. doi: 10.1186/s13075-017-1480-0.
8. Neumann A, Haschka J, Kleyer A, Schuster L, Englbrecht M, Berlin A, et al. Cortical bone loss is an early feature of axial spondyloarthritis. Arthritis Res Ther. 2018; 20 (1): 202. doi: 10.1186/s13075-018-1620-1
9. Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006; 45 (10): 1197-1200. doi: 10.1093/rheumatology/kel072
10. Altindag O, Erel O, Soran N, Celik H, Selek S. Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int. 2008; 28: 317-321. doi: 10.1007/s00296-007-0452-0
11. Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009; 44 (5): 772-776. doi: 10.1016/j.bone.2008.12.028
12. Başkan BM, Sivas F, Inal EE, Duran S, Elverici E, Ozoran K, et al. Comparison of the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score in Turkish patients with ankylosing spondylitis. Clin Rheumatol. 2010; 29 (1): 65-70. doi: 10.1007/s10067-009-1290-0
13. Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018; 48 (1): 44-52. doi: 10.1016/j.semarthrit.2017.12.001
14. Özmen M, Sebzeci D, Akgöl E, Sari I. The effect of conventional treatment on biomarkers related with vascular injury in patients with ankylosing spondylitis. RAED Dergisi. 2014; 6 (2): 43-47. doi: 10.2399/raed.14.66376
15. Derakhshan MH, Goodson NJ, Packham J, Sengupta R, Marzo-Ortega H, Molto A, et al. Hip osteoporosis and vertebral fractures are associated with younger age at diagnosis of spondyloarthritis: results from the COMOSPA study. Ann Rheum Dis. 2017; 76 (Suppl 2): 13083-1308. doi: 1136/annrheumdis-2017-eular.3439
16. Zhang M, Li XM, Wang GS, Tao JH, Chen Z, Ma Y, et al. The association between ankylosing spondylitis and the risk of any, hip, or vertebral fracture: A meta-analysis. Medicine. 2017; 96 (50): 8458. doi: 10.1097/MD.0000000000008458
17. Беневоленская Л.И., Лесняк О.М. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Москва: ГЭОТАР-Медиа, 2011. 14 с
18. Van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis. 2005; 64 (12): 1761-1764. doi: 10.1136/ard.2005.036491
19. Malochet-Guinamand S, Pereira B, Tatar Z, Tournadre A, Moltó A, Dougados M, et al. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskelet Disord. 2017; 18 (1): 357. doi: 10.1186/s12891-017-1718-7
20. Borcan M, Matei D, Popescu R. Management of osteoporosis in ankylosing spondylitis. Osteoporosis Int. 2011; 22 (1): 309-310
21. Kaya A, Ozgocmen S, Kamanli A, Ardicoglu O. Bone loss in ankylosing spondylitis: does syndesmophyte formation have an influence on bone density changes? Med Princ Pract. 2009; 18 (6): 470-476. doi: 10.1159/000235897
22. Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007; 19 (4): 340-345. doi: 10.1097/BOR.0b013e328133f57b
23. Mermerci Başkan B, Pekin Doğan Y, Sivas F, Bodur H, Ozoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int. 2010; 30 (3): 375-381. doi: 10.1007/s00296-009-0975-7
24. Lange U, Boss B, Teichmann J, Klör HU, Neeck G. Serum amyloid A - an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000; 19 (4): 119-122. doi: 10.1007/s002960050114
25. Юшина С.А. Особенности метаболизма костной ткани у больных анкилозирующим спондилоартритом: автореф. дис. … канд. мед. наук. Оренбург, 2012. 27 с
26. Toussirot E, Michel F, Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology (Oxford). 2001; 40 (8): 882-888. doi: 10.1093/rheumatology/40.8.882
27. Sivri A, Kilinc S, Gokce-Kutsal Y. Ariyurek M. Bone mineral density in ankylosing spondylitis. Clin Rheumatol. 1996; 15 (1): 51-54
28. Capaci K, Hepguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med. J. 2003; 44 (3): 379-384. doi: 10.3349/ymj.2003.44.3.379
29. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatology. 2005; 32 (7): 1290-1298
30. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003; 23 (2): 61-66. doi: 10.1007/s00296-002-0237-4
31. Grubisić F, Grazio S, Balenović A, Nemcić T, Kusić Z. Osteoporosis, spinal mobility and chest expansion index in patients with ankylosing spondylitis. Coll Antropol. 2014; 38 (1): 63-68
32. Gratacos J, Collado A, Pons F, Osaba M, Sanmartí R, Roqué M, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: follow up study. Arthritis Rheum. 1999; 42 (11): 2319-2324. doi: 10.1002/1529-0131(199911)42:11<2319:: AID-ANR9>3.0.CO;2-G
33. Wang D, Hou Z, Gong Y, Chen S, Lin L, Xiao Z. Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. PLoS One. 2017; 12 (12): e0189569. doi: 10.1371/journal.pone.0189569
34. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatology. 2002; 29 (7): 1430-1436
35. Chen J, Veras MM, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2004; (3): CD004524. doi: 10.1002/14651858.CD004524.pub4
36. Рожнова О.М., Фаламеева О.В., Садовой М.А. Патофизиология костной ткани при остеопорозе (обзор литературы) // Международный журнал прикладных и фундаментальных исследований. 2015. № 9. С. 666-669
37. Riches PL, McRorie E, Fraser WD, Determann C, van’t Hof R, Ralston SH. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med. 2009; 361 (15): 1459-1465. doi: 10.1056/NEJMoa0810925
38. Hauser B, Riches PL, Gilchrist T, Visconti MR, Wilson JF, Ralston SH. Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. 2015; 74 (8): 1631-1632. doi:10.1136/annrheumdis-2014-207219
39. Hauser B, Zhao S, Visconti MR, Riches P, Fraser WD, Piec I, et al. Autoantibodies to Osteoprotegerin are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study. Calcif Tissue Int. 2017; 101 (4): 375-383. doi: 10.1007/s00223-017-0291-2
40. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis in patients with active disease: a crosssectional analysis. Osteoporos Int. 2011; 22 (5): 1431-1439. doi: 10.1007/s00198-010-1338-7
41. Mermerci Başkan B, Pekin Doğan Y, Sivas F, Bodur H, Ozoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int. 2010; 30 (3): 375-381. doi: 10.1007/s00296-009-0975-7
42. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int. 2006; 17 (1): 61-67. doi: 10.1007/s00198-005-1900-x
43. Burton LA, Sumukadas D. Optimal management of sarcopenia. Clinical Interventions in Aging. 2010; 5: 217-228. doi: 10.2147/CIA.S11473
44. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48 (1): 16-31. doi: 10.1093/ageing/afy169
45. Поворознюк В.В., Бинкли Н., Дзерович Н.И., Поворознюк Р.В. Саркопения. Киев: ПАТ «Вiпол», 2016. 180 с
46. Crepaldi G, Maggi S. Sarcopenia and osteoporosis: а hazardous duet. J Endocrinol Invest. 2005; 28 (10 Suppl): 66-68
47. Шостак Н.А., Мурадянц А.А., Кондрашов А.А., Денисова С.Н. Клиническая эффективность быстрорастворимого козьего молока в комплексной терапии и профилактике остеопороза у больных ревматоидным артритом // Вопросы питания. 2014; Т. 83. № 5. С. 79-85
48. Di Monaco M, Castiglioni C, Vallero F, Di Monaco R, Tappero R. Sarcopenia is more prevalent in men than in women after hip fracture: a cross-sectional study of 591 in patients. Arch Gerontol Geriatr. 2012; 55 (2): 48-52. doi: 10.1016/j.archger.2012.05.002 PMID: 22647380
49. Hida T, Ishiguro N, Shimokata H, Sakai Y, Matsui Y, Takemura M, et al. High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture. Geriatr Gerontol Int. 2013; 13 (2): 413-420. doi: 10.1111/j.1447-0594.2012.00918.x
50. El Maghraoui A, Ebo’o FB, Sadni S, Majjad A, Hamza T, Mounach A. Is there a relation between pre-sarcopenia, sarcopenia, cachexia and osteoporosis in patients with ankylosing spondylitis? BMC Musculoskeletal Disorders. 2016; 17: 268. DOI: 10.1186/s12891-016-1155-z
Рецензия
Для цитирования:
Раскина Т.А., Малышенко О.С., Пирогова О.А., Григорьева И.И. ПРОБЛЕМА ОСТЕОПОРОЗА ПРИ АНКИЛОЗИРУЮЩЕМ СПОНДИЛИТЕ. Фундаментальная и клиническая медицина. 2019;4(1):56-65.
For citation:
Raskina T.A., Malyshenko O.S., Pirogova O.A., Grigorieva I.I. OSTEOPOROSIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Fundamental and Clinical Medicine. 2019;4(1):56-65. (In Russ.)